• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Neurological toll of COVID-19
AbstractThe first case of coronavirus illness was discovered in Wuhan, China, in January 2020 and quickly spread worldwide within the next couple of months. The condition was initially only linked with respiratory disorders. After the evolution of various variants of the SARS-CoV-2, the critical impact of the virus spread to multiple organs and soon, neurological disorder manifestations started to appear in the infected patients. The review is focused on the manifestation of various neurological disorders linked with both the central nervous system and peripheral nervous system. Disorders such as cytokine release syndrome,...
Source: Neurological Sciences - January 16, 2022 Category: Neurology Source Type: research

NIH Slated for 7 percent Budget Cut
The President has proposed a $38.7 billion budget for the National Institutes of Health in fiscal year (FY) 2021. This translates to a $3 billion or 7 percent cut in the agency’s funding compared to FY 2020. The NIH budget request includes a $50 million initiative to use artificial intelligence (AI) to develop a better understanding of the causes of chronic diseases and to identify early treatments. This plan is in line with the Administration’s “Industries of the Future” effort, which supports using and developing AI across sectors. The budget would provide $50 million for the Childhood Cancer ...
Source: Public Policy Reports - February 18, 2020 Category: Biology Authors: AIBS Source Type: news

CNS Summit 2017 Abstracts of Poster Presentations
Conclusion: This novel technology discriminates and quantifies subtle differences in behavior and neurological impairments in subjects afflicted with neurological injury/disease. KINARM assessments can be incorporated into multi-center trials (e.g., monitoring stroke motor recovery: NCT02928393). Further studies will determine if KINARM Labs can demonstrate a clinical effect with fewer subjects over a shorter trial period. Disclosures/funding: Dr. Stephen Scott is the inventor of KINARM and CSO of BKIN Technologies.   Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF Presenter: Chelsky...
Source: Innovations in Clinical Neuroscience - November 1, 2017 Category: Neuroscience Authors: ICNS Online Editor Tags: Assessment Tools biomarkers Cognition Current Issue Drug Development General Genetics Medical Issues Neurology Patient Assessment Psychopharmacology Scales Special Issues Supplements Trial Methodology clinical trials CNS Su Source Type: research